Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.84 |
| ▸ | MTOR | P42345 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277393 | 0.91 | MTOR (1.00) | PIK3CAMTOR | |
| SCHEMBL2283291 | 0.90 | PIK3CA (1.00) | PIK3CAMTOR | |
| SCHEMBL2283280 | 0.90 | PIK3CA (1.00) | PIK3CAMTOR | |
| SCHEMBL18133244 | 0.90 | PIK3CA (1.00) | PIK3CAMTOR | |
| SCHEMBL2284431 | 0.87 | MTOR (0.81) | PIK3CAMTOR | |
| SCHEMBL2284427 | 0.87 | PIK3CA (1.00) | PIK3CAMTOR | |
| SCHEMBL2277245 | 0.85 | MTOR (1.00) | PIK3CAMTOR | |
| SCHEMBL2279511 | 0.84 | MTOR (1.00) | PIK3CAMTOR | |
| SCHEMBL2277866 | 0.84 | MTOR (1.00) | PIK3CAMTOR | |
| SCHEMBL2285051 | 0.84 | MTOR (1.00) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356120-B1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER (US) | 2016-10-12 | — | — | EP | claimed |
| EP-2356120-B1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2356120-B1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| US-8791131-B2 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | PFIZER INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791131-B2 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | PFIZER INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2010038165-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PIK3CA, PIK3CD, PIK3R5 | PIK3CA 1/4885MTOR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.